Epithelioid Hemangioma of Bone

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Epithelioid Hemangioma of Bone trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1/2

NCT06239272

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S…

The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk * To estimate the 3-year event-free survival…

United States139 participantsStarted 2024-03-27

Treatment: Surgical resection, Proton beam radiation therapy

All recent trials (6 shown)

CompletedPhase 2

NCT02815995

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

The goal of this clinical research study is to learn if the combination of durvalumab and tremelimumab can help to control sarcoma. The safety of this drug comb…

United States57 participantsStarted 2016-08-16

Treatment: Durvalumab, Tremelimumab

CompletedPhase 1/2

NCT03277924

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Phase I-II, single-arm, non-randomized, open-label, multicenter, international clinical trial, with two stages. Stage one has two cohorts (soft tissue sarcoma a…

Italy, Spain197 participantsStarted 2017-05-31

Treatment: Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo]

Epithelioid Hemangioma of Bone

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S…

All recent trials (6 shown)

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S…

All recent trials (6 shown)

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metast…

Epithelioid Hemangioma of Bone And Soft Tissue

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis